We enrolled 3xTg-AD mice at 12 months of age, a timepoint in which these animals exhibit all the hallmarks of the disease, and treated with an anti-TNFSF10 monoclonal antibody, as previously described (Cantarella et al. 2015). Subsequently the immune response and pathological features were assessed. Here, TNFSF10 is linked to Alzheimer disease.